A research team affiliated with UNIST has made an important discovery that explains why liver cancers associated with obesity and metabolic disorders are more aggressive and less responsive to conventional treatments. Study shows that a specific signaling pathway involving endotrophin—a protein secreted during liver fibrosis—and the receptor protein CD44 promotes tumor malignancy and drug resistance.
Please follow and like us:
